Untitled

doi:10.18632/oncotarget.v5i8

Cited by 4 publications

(5 citation statements)

References 129 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on the information provided, it seems that C1GALT1 plays a crucial role in the glycosylation process, affecting the production of Tn antigen and the subsequent formation of downstream proteins like the core 1 structure. The mechanism of action of C1GALT1 is multifaceted and involves the regulation of target protein expression, phosphorylation, and localization, ultimately controlling various biological processes such as tumor proliferation, migration, and adhesion ( 25 , 53 , 54 ). In colorectal cancer cells, elevated T-synthase activity and overexpression of Cosmc and T synthase have been observed ( 55 , 56 ).…”

Section: C1galt1 In Colorectal Cancermentioning

confidence: 99%

“…C1GALT1, a key player in colon cancer pathogenesis, significantly influences the behavior and properties of cancer cells. This enzyme’s overexpression alters O-glycans on Fibroblast Growth Factor Receptor 2 (FGFR2), a receptor tyrosine kinase overexpressed in colorectal cancer ( 53 ). FGFR2 is crucial for cellular processes like proliferation, survival, migration, and differentiation ( 70 , 71 ).…”

Section: C1galt1 In Colorectal Cancermentioning

confidence: 99%

“…FGFR2 is crucial for cellular processes like proliferation, survival, migration, and differentiation ( 70 , 71 ). The modification of FGFR2 by C1GALT1, as evidenced by the presence of sTn on FGFR2, enhances its phosphorylation, promoting invasive behavior and cancer stem-like properties in colon cancer cells ( 53 , 72 – 76 ). Furthermore, C1GALT1’s role extends to the epithelial-mesenchymal transition (EMT) in cancer cells.…”

Section: C1galt1 In Colorectal Cancermentioning

confidence: 99%

“…However, incomplete glycosylation caused by various factors can lead to the production of TACAs as described above. These truncated O-glycans possess carcinogenic characteristics and can directly induce cell growth and invasion (52).…”

Section: C1galt1 In Glycosylationmentioning

confidence: 99%

“…It has also been observed that T-synthase activity and Cosmc, a crucial chaperone for its expression, were lower in Tn-positive CRC tissues compared to negative tissues (62). Others have proposed that the characteristic truncation of O-glycans found in pancreatic cancer and most epithelial cancers is not due to somatic mutations, but at least partially due to epigenetic silencing of COSMC companion genes caused by promoter hypermethylation (52). While, Sun (34) et al have found that LOH that is a common mechanism of loss of gene function in tumorigenesis occurs in Cosmc, but not C1GALT1, through studies of CRC cells.…”

Section: C1galt1 and Cosmcmentioning

confidence: 99%

See 4 more Smart Citations

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

Tian,

Yu,

Chu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

C1GALT1 plays a pivotal role in colorectal cancer (CRC) development and progression through its involvement in various molecular mechanisms. This enzyme is central to the O-glycosylation process, producing tumor-associated carbohydrate antigens (TACA) like Tn and sTn, which are linked to cancer metastasis and poor prognosis. The interaction between C1GALT1 and core 3 synthase is crucial for the synthesis of core 3 O-glycans, essential for gastrointestinal health and mucosal barrier integrity. Aberrations in this pathway can lead to CRC development. Furthermore, C1GALT1's function is significantly influenced by its molecular chaperone, Cosmc, which is necessary for the proper folding of T-synthase. Dysregulation in this complex interaction contributes to abnormal O-glycan regulation, facilitating cancer progression. Moreover, C1GALT1 affects downstream signaling pathways and cellular behaviors, such as the epithelial-mesenchymal transition (EMT), by modifying O-glycans on key receptors like FGFR2, enhancing cancer cell invasiveness and metastatic potential. Additionally, the enzyme's relationship with MUC1, a mucin protein with abnormal glycosylation in CRC, highlights its role in cancer cell immune evasion and metastasis. Given these insights, targeting C1GALT1 presents a promising therapeutic strategy for CRC, necessitating further research to develop targeted inhibitors or activators. Future efforts should also explore C1GALT1's potential as a biomarker for early diagnosis, prognosis, and treatment response monitoring in CRC, alongside investigating combination therapies to improve patient outcomes.

show abstract

Section: C1galt1 In Colorectal Cancermentioning

confidence: 99%

Section: C1galt1 In Colorectal Cancermentioning

confidence: 99%

Section: C1galt1 In Colorectal Cancermentioning

confidence: 99%

Section: C1galt1 In Glycosylationmentioning

confidence: 99%

Section: C1galt1 and Cosmcmentioning

confidence: 99%

See 3 more Smart Citations

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

Tian,

Yu,

Chu

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

et al. 2018

View full text Add to dashboard Cite

IMPORTANCE Endocrine therapy-induced alopecia (EIA) has been anecdotally reported but not systematically described. OBJECTIVE To characterize EIA in patients with breast cancer. DESIGN, SETTING, AND PARTICIPANTS Retrospective cohort study of 112 patients with breast cancer, diagnosed with EIA from January 1, 2009, to December 31, 2016, the patients were examined at the dermatology service in a large tertiary care hospital and comprehensive cancer center. MAIN OUTCOMES AND MEASURES The clinical features, alopecia-related quality of life (QoL), and response to minoxidil of EIA in patients with breast cancer were assessed. Data from the Hairdex Questionnaire was used to assess the impact of the alopecia on patients QoL. Higher score indicates lower QoL (0-100 score). Efficacy of minoxidil was measured at 3 or 6 months by a single-blinded investigator through standardized clinical photographs of the scalp. RESULTS A total of 112 female patients with breast cancer were included (median [range] age, 60 [34-90] years). A total of 104 patients (93%) had standardized clinical photographs; of these, 59 patients (53%) had trichoscopy images available at baseline, and 46 patients (41%) were assessed for response to minoxidil. Alopecia was attributed to aromatase inhibitors in 75 patients (67%) and tamoxifen in 37 (33%). Severity was grade 1 in 96 of 104 patients (92%), and the pattern was similar to androgenetic alopecia. The predominant trichoscopic feature at baseline was the presence of vellus hairs and intermediate-and thick-diameter terminal hair shafts. A negative impact on QoL was reported, with a higher effect in the emotion domain according to the Hairdex score (mean [SD], 41.8 [21.3]; P < .001). After treatment with topical minoxidil, moderate or significant improvement in alopecia was observed in 37 of 46 patients (80%). CONCLUSIONS AND RELEVANCE Endocrine therapies are associated with a pattern alopecia similar to androgenetic-type, consistent with the mechanism of action of causal agents. A significant negative impact on QoL was reported by patients, despite mostly mild alopecia severity.

show abstract

Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer

et al. 2020

View full text Add to dashboard Cite

IMPORTANCE Persistent radiation-induced alopecia (pRIA) and its management have not been systematically described.OBJECTIVE To characterize pRIA in patients with primary central nervous system (CNS) tumors or head and neck sarcoma. DESIGN, SETTING, AND PARTICIPANTSA retrospective cohort study of patients from January 1, 2011, to January 30, 2019, was conducted at 2 large tertiary care hospitals and comprehensive cancer centers. Seventy-one children and adults diagnosed with primary CNS tumors or head and neck sarcomas were evaluated for pRIA. MAIN OUTCOMES AND MEASURESThe clinical and trichoscopic features, scalp radiation dose-response relationship, and response to topical minoxidil were assessed using standardized clinical photographs of the scalp, trichoscopic images, and radiotherapy treatment plans. RESULTSOf the 71 patients included (median [range] age, 27 [4-75] years; 51 female [72%]), 64 (90%) had a CNS tumor and 7 (10%) had head and neck sarcoma. Alopecia severity was grade 1 in 40 of 70 patients (56%), with localized (29 of 54 [54%]), diffuse (13 of 54 [24%]), or mixed (12 of 54 [22%]) patterns. The median (range) estimated scalp radiation dose was 39.6 (15.1-50.0) Gy; higher dose (odds ratio [OR], 1.15; 95% CI, 1.04-1.28) and proton irradiation (OR, 5.7; 95% CI, 1.05-30.8) were associated with greater alopecia severity (P < .001), and the dose at which 50% of patients were estimated to have severe (grade 2) alopecia was 36.1 Gy (95% CI, 33.7-39.6 Gy). Predominant trichoscopic features included white patches (16 of 28 [57%]); in 15 patients, hair-shaft caliber negatively correlated with scalp dose (correlation coefficient, −0.624; P = .01). The association between hair density and scalp radiation dose was not statistically significant (−0.381; P = .16). Twenty-eight of 34 patients (82%) responded to topical minoxidil, 5% (median follow-up, 61 [interquartile range, 21-105] weeks); 4 of 25 (16%) topical minoxidil recipients with clinical images improved in severity grade. Two patients responded to hair transplantation and 1 patient responded to plastic surgical reconstruction.CONCLUSIONS AND RELEVANCE Persistent radiation-induced alopecia among patients with primary CNS tumors or head and neck sarcomas represents a dose-dependent phenomenon that has distinctive clinical and trichoscopic features. The findings of this study suggest that topical minoxidil and procedural interventions may have benefit in the treatment of pRIA.

show abstract

Untitled

Cited by 4 publications

References 129 publications

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

Unraveling the role of C1GALT1 in abnormal glycosylation and colorectal cancer progression

Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer

Assessment and Treatment Outcomes of Persistent Radiation-Induced Alopecia in Patients With Cancer

Contact Info

Product

Resources

About